Dai et al. developed transferrin paclitaxel loaded lipid NPs (TPLN) which showed enhanced targeting to the HL-60 cancer cells compared to that of the paclitaxel-loaded NPs (PLN) due to the ability of transferrin to target leukemia cells leading to remarkable apoptosis of leukemia cells [106]. The gene discussed is TF; the disease is cancer.